Another Hepatitis C drug in the market
26 March 2015 | News | By BioSpectrum Bureau
Another Hepatitis C drug in the market
Around 12-18 million patients are estimated to be infected with Hepatitis C, Cipla said
Cipla has announced the launch of generic drug, Sofosbuvir for treating chronic Hepatitis C. It is available under the brand name 'Hepcvir'.
"Following the non-exclusive licensing agreement signed with Gilead Sciences in September last year to manufacture and market chronic Hepatitis C medicines, Cipla is now all set to make the drug Sofosbuvir available to Indian patients in a week's time," the company said in a statement.
The company further said that the availability of product in other markets is subject to approvals from the regulatory authorities in the respective countries.
"Cipla has always brought accessible and affordable medicines to fight against diseases like AIDS and Hepatitis B; hence, it has made it a priority to bring Hepcvir to patients in India as well as the other developing nations," said Mr Subhanu Saxena, MD and global CEO, Cipla.
